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Background: Gestational diabetes mellitus (GDM) is a common pregnancy condition. In this study, the risk of
having a history of previous GDM (pGDM) on serum homocysteine level was assessed
Methods: Biomedical parameters, serum homocysteine, Insulin, homeostatic model assessment (HOMA) in women
with (n = 52) and without pGDM (n = 51) were assessed. According to their current status of Oral Glucose Tolerance
Test (GTT), the participants in each group were divided into two subgroups of normal or impaired GTT.
Results: Mean serum homocysteine in normal women was 8.56 ± 3.19 vs 11.44 ± 7.34 μmol/L (p < 0.01) in women
with pGDM. Two groups had significant differences in respect to serum insulin levels (8.35 ± 5.12 vs 12.48 ± 5.44,
p < 0.002), and HOMA-IR (1.90 ± 1.30 vs 2.91 ± 1.30, p < 0.002). In women without pGDM, serum homocysteine in
normal and impaired GTT were 7.60 ± 1.69 and 10.52 ± 3.65 μmol/L (p = 0.03), respectively, while in women with
pGDM, the figures were 8.38 ± 2.52 and 14.00 ± 10.17 (p < 0.01), respectively. In multi regression analysis an
association between history of GDM and homocysteine levels was presented (OR: 7.71, 95% CI: 1.67-35.42, p < 0.001).
Conclusion: A trend of elevation of homocysteine is presented in women with pGDM, that is more prominent in
women with impaired GTT, and shows a significant correlation with history of GDM. Further studies with larger sample
size are suggested.
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Gestational diabetes mellitus (GDM) is a common con-
dition which is defined as a different degree of the glu-
cose intolerance that begins or is first detected during
pregnancy. GDM affects between 2% and 5% of pregnant
women in the united state [1]. In Iran it complicates 4-8%
of pregnancies [2]. The pathogenesis of GDM is very simi-
lar to that of type 2 diabetes (T2D), in which both pancre-
atic insulin release and chronic insulin resistance have
roles. GDM and impaired glucose tolerance during preg-
nancy are shown to be associated with future metabolic
dysfunction and diabetes separate from other clinical risk
factors [3]. The GDM patients may also show early* Correspondence: fakhrzad@tums.ac.ir
1Elderly Health Research Center, Endocrinology and Metabolism population
Sciences Institute, Tehran University of Medical Sciences, North Karegar
Avenue, Dr Shariati Hospital, 5th floor, Tehran 1411413137, Iran
2Endocrinology and Metabolism Research Center, Endocrinology and
Metabolism Research InstituteTehran University of Medical Sciences,
Tehran, Iran
© 2013 Alatab et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the ormarkers of vascular disease such as endothelial dysfunc-
tion [4] which may make them susceptible to premature
atherosclerosis and coronary heart disease.
Hyperhomocysteinemia, as a major independent risk
factor for vascular disease, has been found in some studies
to be associated with clinical conditions of insulin resistance
[5-8]. In a study by Meigs et al. [7] hyperhomocysteinemia
was associated with hyperinsulinemia. The authors claimed
that hyperhomocysteinemia may partially account for an in-
creased risk of cardiovascular disease seen in patients with
insulin resistance. Though in some studies no or negative
correlation was found between hyperhomocysteinemia and
insulin resistance syndrome [9].
As we mentioned here the diagnosis of GDM signals a
greater risk of developing diabetes. On the other hand,
some studies points that hyperhomocysteinemia may be
involved in development of insulin resistance conditions.
Therefore in this study we aimed to investigate the associ-
ation between having a history of previous GDM (pGDM)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Alatab et al. Journal of Diabetes & Metabolic Disorders 2013, 12:34 Page 2 of 5
http://www.jdmdonline.com/content/12/1/34and hyperhomocysteinemia. We also sought to see the
correlation between hyper hyperhomocysteinemia with in-
sulin resistance condition. To perform this, we measured
the serum levels of homocysteine in women with and
without pGDM and evaluated to see that whether insulin
resistance could exceed what that has been observed in
normal pregnancy.Methods
Study population
This study was performed in the Endocrinology and Me-
tabolism Research Center of Tehran University of Medical
Sciences. Participants were randomly drawn from the list
of pregnant women who attended the obstetrics clinic at
Dr. Shariati Hospital for regular prenatal care between
2005–2009. A total of 51 non-pregnant women with his-
tory of GDM (pGDM) and 52 non-pregnant unaffected
women as control subjects with a mean of 4 years after
their index pregnancy were enrolled. Two groups were
matched based on their ages. The protocol of study was
approved by the ethics committee of Tehran University of
Medical Sciences and the participants signed their in-
formed consent at the time of recruitment.
All of the participants underwent physical examination
and anthropometric evaluations at the time of recruit-
ment. By means of a special questionnaire, the maternal
data including age, parity, habits and pregnancy events
were collected. The inclusion criteria were defined as
non menopause non pregnant women, aged betweenTable 1 Anteropometric and biochemical characteristics of pa
GDM status pGDM
Variables n = 51
Age (year) 32.27 ± 5.01
BMI (kg/m2) 28.12 ± 3.57
FBS (mg/dl) 100.47 ± 31.90
TG (mg/dl) 127.90 ± 65.84
Cholesterol (mg/dl) 195.67 ± 33.86
LDL cholesterol (mg/dl) 108.27 ± 24.13
HDL cholesterol (mg/dl) 50.00 ± 10.13
Serum insulin 12.48 ± 5.44
Serum creatinine (mg/dl) 0.80 ± 0.09
Serum B12 (pg/ml) 437.67 ± 131.35
Serum folic acid (ng/ml) 5.44 ± 2.69
Serum Homocysteine (μmol/L) 11.44 ± 7.34
Systolic Blood Pressure (mmHg) 119.47 ± 13.51
Diastolic Blood Pressure (mmHg) 76.66 ± 10.90
HbA1c (%) 5.42 ± 1.29
Uric acid 4.87 ± 1.20
HOMA-IR 2.91 ± 1.3020–44 years old. Patients who had pre-existing hyperten-
sion, symptomatic cardiovascular disease, using vitamin B
supplements, current or previous smokers, or had a med-
ical condition that influenced the homocysteine level
(chronic renal failure, hypothyroidism, a history of breast
or ovarian cancer) were excluded from the study.
Participants were stratified based on American Dia-
betes Association recommendation [10]. Those with
fasting blood sugar (FBS) < 126 mg/dl and 2-h post glu-
cose load < 140 mg/dl categorized as normal glucose tol-
erance (N-GTT) and patients with FBS < 126 mg/dl and
2-h post glucose load ≥ 140 mg/dl as impaired glucose
tolerance (I- GTT).
Weight and height were measured. BMI was calculated
by dividing weight (kg) by square of height (m). Blood
pressure was measured with an automatic sphygmoman-
ometer in the sitting position.Laboratory measurement
The blood sample for biochemical parameters were
taken after an overnight fasting. Patients then underwent
a 75- g oral glucose tolerance test at 2 h after glucose
load, the blood samples were collected again. FBS, trigly-
ceride (TG), total cholesterol, HDL cholesterol and LDL
cholesterol were measured by enzymatic method (Pars
Azmoon, Iran). Serum folate and vitamin B12 were mea-
sured by Radioimmunoassay (RIA assay, Simul TRAC, ICN
Pharmaceutical). Homocysteine was measured by HPLC
method. Plasma insulin was determined by immunoassayrticipants by GDM status
Control P
n = 52
32.23 ± 6.14 0.97
27.58 ± 5.69 0.66
92.15 ± 14.75 0.21
109.12 ± 45.50 0.19
176.50 ± 37.84 0.02
92.27 ± 24.71 < 0.001
50.50 ± 10.24 0.83
8.35 ± 5.12 < 0.001
0.82 ± 0.11 0.34
401.46 ± 154.93 0.31
5.12 ± 2.62 0.65
8.56 ± 3.19 0.01
116.07 ± 14.19 0.30
71.69 ± 8.59 0.04
5.22 ± 0.67 0.49
4.67 ± 1.08 0.48
1.90 ± 1.30 <0.001
Table 2 Serum homocysteine concentration according to glucose tolerance test status
pGDM P Control P
(n = 51) value (n = 52) value
N-GTT I-GTT N-GTT I-GTT
(n = 39) (n = 12) (n = 45) (n = 7)
Homocysteine(μmol/L) 8.38 ± 2.52 14.00 ± 10.17 <0.01 7.60 ± 1.69 10.52 ± 3.65 0.03
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Inc., Lake Forest, CA, USA). Homoeostasis model assess-
ment (HOMA -IR) was calculated as [fasting plasma glu-
cose (mmol/L) x fasting insulin (μU/mL) / 22.5].Statistical analysis
Statistical analysis was performed using Statistical Pack-
age for the Social Sciences (SPSS, version 18, Chicago, IL,
USA). Values less than 0.05 were considered significant.
Normality of values was tested by Kolmogorov- Smirnov
test. Comparison of clinical and biochemical variables be-
tween groups were tested by t-test. Evaluation of homo-
cysteine concentration according to glucose tolerance test
status was done using one way ANOVA. Multiple logistic
regression analysis was performed with categorized homo-
cysteine (homocysteine > 14 vs ≤ 14) [11] as a dependent
variable, and GDM status as an independent variable.
Model was adjusted for serum folic acid, vitamin B12,
FBS, TG, Cholesterol, LDL, insulin, diastolic blood pres-
sure and HOMA-IR.Table 3 Coefficients of homocysteine association with
GDM status in a multiple logistic regression mode
Multivariate adjusted OR (95% CI) P
pDGM 7.71 (1.67-35.42) 0.00
Vit B12 0.99 (0.99-1.00) 0.28
Folic acid 1.15 (8.23-1.62) 0.40
Insulin 0.89 ( 0.75-1.06) 0.21
Cholesterol 0.97 (0.94-0.99) 0.03
Diastolic BP 0.99 (0.92-1.08) 0.95
FBS 1.16 (1.08-1.25) 0.00
TG 1.00 (0.98-1.02) 0.54
Adjusted for: VitB12, folic acid, insulin, cholesterol, diastolic blood pressure,
FBS, and TG.Results
Table 1 shows the demographic and biochemical charac-
teristics of participants. The mean ages of participants in
control and pGDM groups were 32.23 ± 6.14 and 32.27 ±
5.01 respectively. No significant difference in respect to
FBS and B12 and folate levels was observed between two
groups, while diastolic blood pressure, cholesterol, LDL,
serum insulin, homocysteine, and HOMA-IR were signifi-
cantly higher in women with pGDM (Table 1).
To evaluate the possible effects of pGDM on insulin re-
sistance condition, each group of participants were divided
based on whether currently they have glucose intolerance
or not. Therefore in group of women with pGDM, sub-
jects were divided into two groups of N-GTT andI-GTT.
The women without pGDM were also divided into two
subgroups of N-GTTand I-GTT (Table 2).
Looking at the patients in this way, we observed a signifi-
cant trend of increase in serum homocysteine concentra-
tion in both groups of women from N-GTT toward I-GTT
(Table 2). In multiple logistic regression analysis, there was
a significant association between homocysteine concentra-
tion and pGDM. Following adjustment for VitB12, folic
acid, insulin, cholesterol, diastolic blood pressure, FBS, and
TG, the significant relation was still present (Table 3).Discussion
Our first observation in this study was an early stage of
insulin resistance in women with pGDM manifested by
higher levels of fasting insulin, and HOMA IR compared
to control group. The failure of pancreatic B cell func-
tion plays an important role in the pathogenesis of insu-
lin resistance. Previous studies showed that impaired
insulin secretion is the key in conversion from normal
glucose tolerance to impaired glucose tolerance and fi-
nally diabetes [12,13]. Although the proper measurement
of B cell function, which is necessary for evaluation of
insulin release,was out of scope of this study, but we couls
state that a glucose impairment existed in our pGDM
population. According to Bonora et al. [14], a HOMA -IR
score ≤ 2.06 could be found in normal non-diabetic popu-
lation. In the absence of local reference data for HOMA -
IR score, we may assume a value of greater than 2.0 to
represent insulin resistance condition. In our study, the
HOMA -IR. of the pGDM was 2.91 compared to 1.90 in
women without pGDM, which could be translated into
that women with pGDM suffer from a state of insulin re-
sistance. Moreover, we observed that women with pGDM
had higher rate of I-GTT than non GDM subjects (23.5%
vs 13.4). Similarly, and more recently, Molęda and his col-
leagues [15] reported a lower rate of normoglycaemia, at
60 and 2 h after glucose load, in women who had GDM
history (57%) within the last 5–12 years compared to non-
GDM women (88%).
Having a higher levels of homocyteine in GDM pa-
tients is reported by previous studies [16,17]. Similarly,
we found a significant difference in levels of serum
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centration of homocysteine. Meanwhile when the subjects
in each group were divided based on their state of glucose
metabolism, no significant changes was presented between
pGDM and non GDM groups who had N-GTT, while this
difference between I-GTT groups were remarkable. In
humans, homocysteine is formed during the metabolism
of methionine and is metabolized by re-methylation or
trans-sulphuration, in which both vitamin B6 and B12
work as the cofactors. The postulation that vitamin status
of participants might influence the result is unlikely, since
the deficiencies and significan difference of folate and B12
were absent in our groups. Glomerular filtration rate as an
indicator of the renal function is another independent de-
terminant of homocysteine concentration [18]. Since the
mean of GFR between two groups were similar (data not
shown), it is unlikely that the higher levels of homocys-
teine is the result of more progressive kidney damage and
more decreased clearance of homocysteine. Therefore, the
weight of evidence from the present study may indicate
that variations in plasma total homocysteine concentra-
tions could be dependent to insulin sensitivity state,
howeverwith this analysis, we can not make apparent the
pathophysiological reason behind increased homocysteine
in IGGT women.
In this study we found an association between history
of GDM and high levels of homocysteine. We can not
comment on that whether high levels of homocysteine
are caused by the previous presence of impaired glucose
tolerance in GDM subjects or patients who developed
GDM had higher succeptibility to have a higher levels of
homocysteine. Eitherway, presence of abnormalities of glu-
cose metabolism are an indicator a manifestation of the
clustering of several metabolic abnormalities, including
dyslipidemia, hypertension, insulin resistance, and, there-
fore, increased cardiovascular risk. On the otherhand, epi-
demiological, retrospective as well as data from prospective
studies support an association between elevated homocys-
teine levels and increased risk of cardiovascular disease
[19]. It has been shown that high levels of plasma homo-
cysteine increase the oxidative stress and decrease the NO
dependent relaxation of endothelium [20]. Taking together,
one can assume that having a history of GDM may present
a multiple risk for cardiovascular disease since it could in-
crease the risk of impairment in glucose metabolism and
also development of higher levels of homocysteine.
We understand that our study has some limitation.
low number of case as well as absence of detailed dietary
information regarding the ingestion of a diet with a high
insulinaemic index is among our limitations.
Conclusion
In conclusion we performed a case–control study in
women with and without history of GDM and observeda trend of increase in serum levels of homocysteine in
pGDM. Further analysis showed that women with I-
GTT had a higher levels of homocysteine. Whether this
elevation was occurred during the course of develop-
ment of glucose metabolism impairment and insulin re-
sistance or is a causal factor needs to be evaluated. A
significant correlation of homocysteine with history of
GDM is an interesting observation of this study that calls
for further studies with larger sample size. Moreover evalu-
ation of endothelial function using flow mediated dilatation
(FMD) in pGDM women with high levels of homocysteine
would be interesting
Abbreviation
GDM: Gestational diabetes mellitus; FBS: Fasting blood sugar; GTT: Glucose
tolerance test; N-GTT: Normal glucose tolerance test; I-GTT: Impaired glucose
tolerance test; TG: Triglyceride; HDL: High density lipoprotein; LDL: Low
density lipoprotein; HOMA: Homoeostasis model assessment.
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